These findings suggest that targeting FXYD3 may be a potential therapeutic strategy, which may also overcome chemoresistance, offering a new therapeutic avenue for patients with advanced ICC. The gene discussed is FXYD3; the disease is intrahepatic cholangiocarcinoma.